Goettingen | Washington DC, January 22, 2013 – Alan Burns, Vice President of Quality Management at pharma and biotech supplier Sartorius Stedium Biotech, has been elected to the Board of Directors of Rx-360. This is an international pharmaceutical supply chain consortium. Burns has been appointed for a three-year term, together with six other individuals from the pharmaceutical and biotech industry, who include both manufacturers and suppliers. Rx-360 is a not for profit association. Its purpose is to enhance the security of the pharmaceutical supply chain and to assure the quality and authenticity of the products moving through this supply chain.
Alan Burns, Vice President of Quality Management at Sartorius Stedim BiotechRx-360 has also elected new officers. Brian Johnson, Senior Director Supply Chain Security at Pfizer will serve as the Rx-360 Chair and Guy Villax, Chief Executive at Hovione, as Vice Chair.
A Profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.” Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 2,850 people, and in 2011 earned sales revenue of 477.3 million euros. www.sartorius.com
A Profile of Rx-360
Rx-360 was formed in 2009 to support an industry-wide commitment to ensuring patient safety by enhancing quality and authenticity throughout the supply chain. The mission of the organization is timely in light of growing attacks and threats to an increasingly complex and global supply chain. Millions of people around the world are treated every day with the vital medicines that pharmaceutical and biotechnology companies provide. Management of the pharmaceutical supply chain has become one of the top public health concerns with respect to consumer safety. The globalization of distribution for both drug components and finished products has introduced many complications that Rx-360 is positioned to help resolve. To learn more about Rx-360, go to the website at www.Rx-360.org.
Contact for Sartorius Stedim Biotech
Marie Fabiunke
Group Corporate Communications
+49.(0)551.308.3199
[email protected]
Contact for Rx-360
Rx-360
An International Supply Chain Consortium
Washington DC
[email protected]